| 1 |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
|
| 2 |
Heinemann V, Boeck S. Perioperative management of pancreatic cancer[J]. Ann Oncol, 2008, 19 (7): 273-278.
|
| 3 |
Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis[J]. Br J Cancer, 2015, 112(3): 580-593.
|
| 4 |
Camara SN, Yin T, Yang M, et al. High risk factors of pancreatic carcinoma[J]. J Huazhong Univ Sci Technolog Med Sci, 2016, 36(3): 295-304.
|
| 5 |
Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer[J]. Jama, 2009, 301(24): 2553-2562.
|
| 6 |
Bao Y, Prescott J, Yuan C, et al. Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer[J]. Gut, 2017, 66(6): 1116-1122.
|
| 7 |
Ghiorzo P, Fornarini G, Sciallero S, et al. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families[J]. J Med Genet, 2012, 49(3): 164-170.
|
| 8 |
Zhen DB, Rabe KG, Gallinger S, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study[J]. Genet Med, 2015, 17(7): 569-577.
|
| 9 |
Zaytouni T, Tsai PY, Hitchcock DS, et al. Critical role for arginase 2 in obesity-associated pancreatic cancer[J]. Nat Commun, 2017, 8(1): 242-242.
|
| 10 |
Li JH, He R, Li YM, et al. Endoscopic ultrasonography for tumor node staging and vascular invasion in pancreatic cancer: a meta-analysis[J]. Dig Surg, 2014, 31(4): 297-305.
|
| 11 |
Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association[J]. Radiology, 2014, 270(1): 248-260.
|
| 12 |
Tirkes T, Sandrasegaran K, Sanyal R, et al. Secretin-enhanced MR cholangiopancreatography: spectrum of findings[J]. Radiographics, 2013, 33(7): 1889-1906.
|
| 13 |
Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study[J]. Clin Gastroenterol Hepatol, 2006, 4(6): 766-781.
|
| 14 |
Okasha HH, Naga MI, Esmat S, et al. Endoscopic ultrasound-guided fine needle aspiration versus percutaneous ultrasound-guided fine needle aspiration in diagnosis of focal pancreatic masses[J]. Endosc Ultrasound, 2013, 2(4): 190-193.
|
| 15 |
Iiboshi T, Hanada K, Fukuda T, et al. Value of cytodiagnosis using endoscopic nasopancreatic drainage for early diagnosis of pancreatic cancer: establishing a new method for the early detection of pancreatic carcinoma in situ[J]. Pancreas, 2012, 41(4): 523-529.
|
| 16 |
Poruk KE, Gay DZ, Brown K, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates[J]. Curr Mol Med, 2013, 13(3): 340-351.
|
| 17 |
Bunger S, Laubert T, Roblick UJ, et al. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview[J]. J Cancer Res Clin Oncol, 2011, 137(3): 375-389.
|
| 18 |
Banfi G, Bravi S, Ardemagni A, et al. CA 19-9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer[J]. Int J Biol Markers, 1996, 11(2): 77-81.
|
| 19 |
Gold DV, Gaedcke J, Ghadimi BM, et al. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma[J]. Cancer, 2013, 119(3): 522-528.
|
| 20 |
Murali Manohar K, Sasikala M, Kvsrr Y, et al. Plasma microRNA192 in combination with serum CA19-9 as non-invasive prognostic biomarker in periampullary carcinoma[J]. Tumour Biol, 2017, 39(3): 1010428317695018.
|
| 21 |
Millner LM, Strotman LN. The future of precision medicine in oncology[J]. Clin Lab Med, 2016, 36(3): 557-573.
|
| 22 |
Poruk KE, Valero V, Saunders T, et al. Circulating tumor cell phenotype predicts recurrence and survival in pancreatic adenocarcinoma[J]. Ann Surg, 2016, 264(6): 1073-1081.
|
| 23 |
Pietrasz D, Pecuchet N, Garlan F, et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker[J]. Clin Cancer Res, 2017, 23(1): 116-123.
|
| 24 |
Denbo JW, Fleming JB. Definition and management of borderline resectable pancreatic cancer[J]. Surg Clin North Am, 2016, 96(6): 1337-1350.
|
| 25 |
Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15(8): 1028-1061.
|
| 26 |
Demir IE, Jager C, Schlitter AM, et al. R0 versus r1 resection matters after pancreaticoduodenectomy, and less after distal or total pancreatectomy for pancreatic cancer[J]. Ann Surg, 2018, 268(6): 1058-1068.
|
| 27 |
Khorana AA, Mangu PB, Katz MHG. Potentially curable pancreatic cancer: american society of clinical oncology clinical practice guideline update summary[J]. J Oncol Pract, 2017, 13(6): 388-391.
|
| 28 |
Wang S, Shi N, You L, et al. Minimally invasive surgical approach versus open procedure for pancreaticoduodenectomy: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2017, 96(50): 8619-8619.
|
| 29 |
Stauffer JA, Coppola A, Villacreses D, et al. Laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institution[J]. Surg Endosc, 2017, 31(5): 2233-2241.
|
| 30 |
Gagner M, Pomp A. Laparoscopic pylorus-preserving pancreatoduodenectomy[J]. Surg Endosc, 1994, 8(5): 408-410.
|
| 31 |
Palanivelu C, Jani K, Senthilnathan P, et al. Laparoscopic pancreaticoduodenectomy: technique and outcomes[J]. J Am Coll Surg, 2007, 205(2): 222-230.
|
| 32 |
Kendrick ML. Laparoscopic and robotic resection for pancreatic cancer[J]. Cancer J, 2012, 18(6): 571-576.
|
| 33 |
Peters JH. Operative techniques in general surgery[J]. Der Radiologe, 2006, 37(4): 259-259.
|
| 34 |
Velanovich V. Case-control comparison of laparoscopic versus open distal pancreatectomy[J]. J Gastrointest Surg, 2006, 10(1): 95-98.
|
| 35 |
Kimura W, Inoue T, Futakawa N, et al. Spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein[J]. Surgery, 1996, 120(5): 885-890.
|
| 36 |
Warshaw AL, Rattner DW, Fernandez-del Castillo C, et al. Middle segment pancreatectomy: a novel technique for conserving pancreatic tissue[J]. Arch Surg, 1998, 133(3): 327-331.
|
| 37 |
Tagaya N, Kasama K, Suzuki N, et al. Laparoscopic resection of the pancreas and review of the literature[J]. Surg Endosc, 2003, 17(2): 201-206.
|
| 38 |
Nau P, Melvin WS, Narula VK, et al. Laparoscopic distal pancreatectomy with splenic conservation: an operation without increased morbidity[J]. Gastroenterol Res Pract, 2009, 2009(1): 846340-846340.
|
| 39 |
Baca I, Bokan I. Laparoscopic segmental pancreas resection and pancreatic cystadenoma[J]. Chirurg, 2003, 74(10): 961-965.
|
| 40 |
Machado MA, Surjan RC, Epstein MG, et al. Laparoscopic central pancreatectomy: a review of 51 cases[J]. Surg Laparosc Endosc Percutan Tech, 2013, 23(6): 486-490.
|
| 41 |
赵国栋，刘荣，马鑫，等. 后腹腔镜胰腺切除术4例报告[J]. 中国实用外科杂志，2012, 32(1): 85-87.
|
| 42 |
刘荣，赵国栋，马鑫，等. 机器人后腹腔镜胰腺手术首例报道[J/CD]. 中华腔镜外科杂志(电子版), 2016, 9(1): 59-60.
|
| 43 |
Giulianotti PC, Coratti A, Angelini M, et al. Robotics in general surgery: personal experience in a large community hospital[J]. Arch Surg, 2003, 138(7): 777-784.
|
| 44 |
Waters JA, Canal DF, Wiebke EA, et al. Robotic distal pancreatectomy: cost effective[J]. Surgery, 2010, 148(4): 814-823.
|
| 45 |
吴志翀，沈柏用，彭承宏. 机器人辅助胰腺微创手术使医患受益的新探讨[J]. 肝胆外科杂志，2015, 23(2): 87-90.
|
| 46 |
薛瑞华. 机器人辅助腹腔镜与传统腹腔镜行胰腺癌手术的Meta分析[J/CD]. 中华腔镜外科杂志(电子版), 2016, 9(1): 19-24.
|
| 47 |
曹月敏，王春城，暴雷，等. da Vinci外科手术系统在胰腺肿瘤外科应用的优势及现状[J]. 中国微创外科杂志，2016, 16(9): 769-773.
|
| 48 |
Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy[J]. Surgery, 2003, 133(5): 521-527.
|
| 49 |
Zhou Y, Shi B, Wu L, et al. A systematic review of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas[J]. HPB (Oxford), 2017, 19(1): 10-15.
|
| 50 |
Jang JY, Kang JS, Han Y, et al. Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study[J]. J Hepatobiliary Pancreat Sci, 2017, 24(7): 426-433.
|
| 51 |
Reddy SK, Tyler DS, Pappas TN, et al. Extended resection for pancreatic adenocarcinoma[J]. Oncologist, 2007, 12(6): 654-663.
|
| 52 |
Tol JA, Gouma DJ, Bassi C, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the international study group on pancreatic surgery (ISGPS)[J]. Surgery, 2014, 156(3): 591-600.
|
| 53 |
Glebova NO, Hicks CW, Tosoian JJ, et al. Outcomes of arterial resection during pancreatectomy for tumor[J]. J Vasc Surg, 2016, 63(3): 721-729.
|
| 54 |
Jegatheeswaran S, Baltatzis M, Jamdar S, et al. Superior mesenteric artery (SMA) resection during pancreatectomy for malignant disease of the pancreas: a systematic review[J]. HPB (Oxford), 2017, 19(6): 483-490.
|
| 55 |
Muller SA, Hartel M, Mehrabi A, et al. Vascular resection in pancreatic cancer surgery: survival determinants[J]. J Gastrointest Surg, 2009, 13(4): 784-792.
|
| 56 |
Selvaggi F, Mascetta G, Daskalaki D, et al. Outcome of superior mesenteric-portal vein resection during pancreatectomy for borderline ductal adenocarcinoma: results of a prospective comparative study[J]. Langenbecks Arch Surg, 2014, 399(5): 659-665.
|
| 57 |
Yekebas EF, Bogoevski D, Cataldegirmen G, et al. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients[J]. Ann Surg, 2008, 247(2): 300-309.
|
| 58 |
Adham M, Singhirunnusorn J. Surgical technique and results of total mesopancreas excision (TMpE) in pancreatic tumors[J]. Eur J Surg Oncol, 2012, 38(4): 340-345.
|
| 59 |
Peparini N, Chirletti P. Mesopancreas: a boundless structure, namely R1 risk in pancreaticoduodenectomy for pancreatic head carcinoma[J]. Eur J Surg Oncol, 2013, 39(12): 1303-1308.
|
| 60 |
Zhan HX, Xu JW, Wu D, et al. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies[J]. Cancer Med, 2017, 6(6): 1201-1219.
|
| 61 |
Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial[J]. Jama, 2013, 310(14): 1473-1481.
|
| 62 |
Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet, 2017, 389(10073): 1011-1024.
|
| 63 |
Sinn M, Bahra M, Liersch T, et al. CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase iii trial[J]. J Clin Oncol, 2017, 35(29): 3330-3337.
|
| 64 |
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the national cancer institute of canada clinical trials group[J]. J Clin Oncol, 2007, 25(15): 1960-1966.
|
| 65 |
虞先濬，刘亮，徐华祥，等. 胰腺癌综合诊治指南(2018版)[J]. 临床肝胆病杂志，2018, 34(10): 77-88.
|